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Abstract The metabolism and biliary excretion of a stretched
bilirubin analog with a p-xylyl group replacing the central CH2
hinge were investigated in normal rats, Gunn rats deficient in
bilirubin conjugation, and TR3 rats deficient in bilirubin
glucuronide hepatobiliary transport. Unlike bilirubin, the analog
was excreted rapidly in bile unchanged in all three rat strains
after intravenous administration. In TR3 rats biliary excretion
of the analog was diminished, but still substantial, demonstrating
that the ATP-binding cassette transporter Mrp2 is not required
for its hepatic efflux. These effects are attributable to differ-
ences in the preferred conformations of bilirubin and the
analog. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Although it is well known that intramolecular hydrogen
bonding and molecular conformation have overwhelming ef-
fects on the biochemistry of macromolecules, their e¡ects on
the metabolism of smaller endogenous molecules and drugs
are frequently ignored. The natural dicarboxylic acids biliru-
bin (1) and biliverdin (2) are paradigmatic examples of small
endogenous molecules (molecular weight V600) whose me-
tabolism seems to be highly dependent on these factors.
With almost identical constitutional structures, molecular
weights, and pKas [1,2], both compounds are anions at phys-
iologic pH and both are cleared e⁄ciently from blood by the
liver [3]. Yet their hepatic metabolism is very di¡erent. Bili-
verdin does not normally occur in the blood or bile of mam-
mals because it is reduced quantitatively to bilirubin [3]. But
when injected intravenously, the fraction that escapes reduc-
tion is excreted rapidly in bile unchanged [4], and in some
non-mammals endogenous biliverdin is excreted intact in
bile [5]. In contrast, bilirubin taken up by the liver is not
secreted in bile, despite the presence of organic anion trans-
porters in the canalicular membrane. Rather, it is converted
by the glucuronosyl enzyme uridinediphosphoglucuronosyl
transferase (UGT)1A1 to monoglucuronides, which are sub-
sequently secreted rapidly from the liver into bile [3]. The
presence of the ATPase Mrp2 (multidrug resistance-associated
protein 2) in the canalicular membrane of the hepatocyte is
essential for their secretion since mutant rats that lack it (TR3
or Eisai rats) do not excrete bilirubin mono- or diglucuronides
e⁄ciently in bile [6^8]. Thus, the apical membrane at the
liver^bile interface seems to be an e¡ective barrier for e¥ux
of unconjugated bilirubin, but not for biliverdin.
The disparate biochemical behavior of 1 and 2 seems to be
rooted in their very di¡erent three-dimensional structures.
Whereas biliverdin adopts extended or helical lock-washer
shaped conformations in solution, bilirubin is constrained
by its saturated carbon atom at C10 to adopt folded, so-called
ridge^tile, structures [9^12]. These are stabilized by a network
of intramolecular hydrogen bonds involving the side-chain
carboxyls and heterocyclic NH and CNO groups. They are
more lipophilic than the conformers adopted by biliverdin in
solution and are thought to be crucially important in the
glucuronidation of bilirubin. For example, when intramolec-
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ular hydrogen bonding is prevented in one or both halves of
the molecule by various chemical manipulations, glucuronida-
tion becomes unnecessary for e¥ux from liver to bile [13^16].
In 1994, Nogales, Anstine and Lightner described the syn-
thesis of the extended bilirubin analog 3. In 3 the central C10
CH2 group has been replaced by a p-xylyl group [17]. This
pushes the two dipyrromethenone moieties too far apart to
permit the normal type of intramolecular hydrogen bonding
that prevails in bilirubin and gives a more £exible, more
folded structure. In this paper we compare the hepatic excre-
tion of 3 in normal rats, in mutant rats that, lacking UGT1A1
activity, are unable to glucuronidate bilirubin (Gunn rats)
[18,19], and in mutant rats (TR3 rats) de¢cient in Mrp2
[6^8]. Our studies show that this stretched bilirubinoid organic
anion is taken up rapidly by the liver and excreted intact in
bile without undergoing glucuronidation and without the need
for Mrp2. However, in the absence of Mrp2 its biliary excre-
tion is somewhat diminished.
2. Materials and methods
2.1. Chemicals
The synthesis and properties of 2,2P-[1,4-phenylenebis(methylene)]-
bis[5-[(1,5-dihydro-3,4-dimethyl-5-oxo-2H-pyrrol-2-ylidene)methyl]-4-
methyl-(Z,Z)-1H-pyrrole-3-propanoic acid (3) have been described
previously [17]. Sodium 2,2P-[(2,17-diethenyl-1,10,19,22,23,24-hexahy-
dro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-diyl)bis[(1-oxo-
3,1-propanediyl)imino]]bis-ethanesulfonate (bilirubin ditaurine amide,
4, disodium salt; sold as ‘bilirubin conjugate’), obtained from Por-
phyrin Products (Logan, UT, USA), showed one main peak on high
performance liquid chromatography (HPLC) and was used without
further puri¢cation. Di-n-octylamine, phosphatidylcholine (Type XV-
E), cholesterol, sodium cholate, taurine and dimethyl sulfoxide
(DMSO) were obtained from Sigma-Aldrich. Methanol and acetic
acid were HPLC grade. Molecular stereopair drawings were made
using Ball and Stick version 3.7.6 by Norbert Mu«ller and Heinz
Falk, Johannes Kepler University Linz using crystal coordinates for
bilirubin IXK [9] and computed global energy minimum coordinates
for rubin 3 [17].
2.2. HPLC
Isocratic HPLC analyses were run using a Beckman-Altex ultra-
sphere-IP 5 Wm C-18 ODS column (25U0.46 cm) ¢tted with a sim-
ilarly packed precolumn (4.5U0.46 cm) and Hewlett-Packard multi-
wavelength diode array detector. Compounds of interest were moni-
tored at their absorbance maxima in the HPLC eluant and peak areas
measured using HP ChemStation software. The elution solvent was
0.1 M di-n-octylamine acetate in 8% aqueous methanol, £ow rate 0.75
ml/min, and column temperature V34‡C.
2.3. Animal studies
The experimental procedures used have been described elsewhere
[20,21]. Brie£y, the femoral vein and common bile duct of adult
male rats weighing s 250 g were cannulated under ketamine anesthe-
sia and a liposomal solution containing phosphatidylcholine (1.5 g),
cholesterol (62 mg), sodium cholate (12.95 g) and taurine (3.75 g) in 1 l
of water was infused (2 ml/h) through the femoral catheter to main-
tain hydration and bile £ow. The total length of the biliary cannula
was 7.5 cm. The animal was placed in a restraining cage under an
infrared heating lamp and, once bile £ow and body temperature were
stable (V30^60 min), the pigment under investigation (0.25 mg), dis-
solved in normal rat serum (1 ml) with the aid of a small volume (0.1
ml) of DMSO, was infused via the femoral vein as a bolus over a
period of 20^45 s. Bile was collected in 20-Wl aliquots into micropipets
from the tip of the bile duct cannula immediately before injection of
pigment and at frequent intervals thereafter for 4 h. Bile samples were
£ash-frozen immediately in dry-ice, then kept at 370‡C until analyzed
by HPLC. Bile £ow rates were measured gravimetrically by periodi-
cally collecting timed 3-min aliquots of bile into tared Pasteur tubes.
For HPLC, frozen bile samples (20 Wl) were mixed with 80 Wl of ice-
cold 0.1 M methanolic di-n-octylamine acetate, microfuged for 30 s,
and the supernate (20 Wl) was injected onto the column. Excretion
curves were derived by plotting integrated HPLC peak areas, normal-
ized to the maximum peak area, against time. The fraction of the
injected dose excreted was estimated by comparing the area under
the biliary excretion curve (HPLC peak area versus time), adjusted
for total bile volume, with the HPLC peak area of the pigment in a
20-Wl sample of the original serum solution injected into the rat. Areas
under biliary excretion curves were determined by the trapezoidal
method using Un-Scan-It software (Silk Scienti¢c, Inc., Orem, UT,
USA). Except for the animal surgery, all procedures were done under
orange or red safelights in a darkroom. Although ¢gures show excre-
tion results from single experiments, all were reproduced in at least
duplicate experiments. Homozygous Gunn rats and TR3 rats were
from colonies maintained at the University of California San Fran-
cisco. Sprague^Dawley rats were from local vendors.
3. Results
On reversed phase HPLC, extended rubin 3 is considerably
more polar than bilirubin (1), but not so polar as bilirubin
Fig. 1. The left-hand column shows HPLC chromatograms of bile
collected just before (t = 0) and shortly after intravenous injection of
a 0.25-mg bolus of rubin 3 into a Gunn rat (a), a Sprague^Dawley
rat (c) and a TR3 (e) rat. The right-hand column shows the biliary
excretion pro¢les for 3 in a Gunn rat (b), a Sprague^Dawley rat (d)
and TR3 (f) rat. The inset in a shows a representative HPLC chro-
matogram of the injectate solution used for each animal. The aster-
isk denotes unchanged 3 and the peaks near 6 min and 9.5 min in c
correspond to endogenous bilirubin di- and monoglucuronides re-
spectively. (Di¡erent HPLC instruments were used in c and e, re-
sulting in di¡erent retention times for 3.)
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ditaurine amide (4). Relative retention factors were 1.0:2.1:9.0
for 4, 3 and bilirubin, respectively. Rubin 3 is more polar than
bilirubin monoglucuronides and less polar than bilirubin di-
glucuronide.
On intravenous injection into the homozygous Gunn rat, 3
was detectable in bile within 3 min in unchanged form, reach-
ing a maximum concentration by 6 min (Fig. 1a,b). No sig-
ni¢cant quantities of yellow metabolites of 3 were detected.
Similar behavior was seen in the Sprague^Dawley rat (Fig.
1c,d) and glucuronide metabolites of 3 were not detected.
The fraction of the injected dose excreted in bile in 4 h was
estimated to be 0.5 and 0.6 in the Gunn and Sprague^Dawley
rat respectively. In four animals (two Gunn, two Sprague^
Dawley) the maximum concentration of unchanged 3 mea-
sured in bile ranged from 1.1 to 1.9 times that in the injectate
and the mean bile £ow rate was 1.7 ml/h.
Rubin 3 was also excreted rapidly in unchanged form when
administered to the TR3 rat (Fig. 1e,f), but the biliary excre-
tion curve was broader. The fraction of the injected dose
excreted in bile in 4 h was estimated to be 0.4 and the max-
imum concentration of unchanged 3 in bile was 0.5 and 0.6
times that in the injectate in duplicate experiments. Mean bile
£ow was 0.9 ml/h.
To better characterize the biliary excretion of 3 in the TR3
rat we ran experiments in which 3 was injected in admixture
with an equal weight of bilirubin ditaurine amide (4), a com-
pound that is excreted extensively in bile in Sprague^Dawley
and Gunn rats and reported to have normal hepatic excretion
in TR3 rats [22,23]. Fig. 2a shows biliary excretion pro¢les
obtained when the two compounds were injected simultane-
ously into a Sprague^Dawley rat. Essentially identical curves
(not shown) were obtained in the Gunn rat. In both strains
the excretion curves for each compound were similar to those
obtained when the two compounds were injected independ-
ently, indicating that at the very small doses used (V1^2
Wmol/kg) neither had an e¡ect on the hepatic uptake or e¥ux
of the other. In duplicate experiments, the fraction of injected
4 excreted in bile was 0.8^1.0 and the fraction of 3, 0.5. The
peak concentration in bile for 4 was 4.4^4.6 times that in the
injectate, and for 3 equal to that in the injectate. These values
are similar to those found when the pigments were injected
individually.
Fig. 2b shows biliary excretion curves obtained when the
recipient was a TR3 rat, in which the mean bile £ow rate was
1.0 ml/h compared to 1.4 ml/h for the animal shown in Fig.
2a. Both pigments were excreted rapidly, but more slowly
than in normal rats or Gunn rats. The curve for 3 lags behind
that of 4 and is considerably broader, consistent with the
greater polarity of 4 compared to 3. In duplicate experiments
the fraction of injected 3 excreted in bile in 4 h was 0.4,
whereas excretion of 4 was quantitative. For each compound,
the ratio of the maximum concentration in bile to the concen-
tration in the injectate was lower than in Gunn or Sprague^
Dawley rats. Thus, for 3 the ratio was 0.4 and for 4 the ratio
was 2.4^3.0.
4. Discussion
Our results show extended rubin 3 is cholephilic. When
administered intravenously to normal rats, to rats de¢cient
in UGT1A1 and incapable of glucuronidating bilirubin, and
to rats lacking the ATP-binding cassette transporter Mrp2, a
substantial fraction was excreted rapidly in bile in unchanged
form, with the peak concentration in bile exceeding that in the
original injectate solution. Rubin 3 di¡ers from natural bili-
rubin 1 in having the two vinyl groups replaced by methyl
groups and the central C10 methylene hinge group replaced
by p-xylyl. Replacement of the vinyl groups by methyls has
been shown to have little e¡ect on the metabolism or lyophilic
properties of bilirubins [21]. Replacing the C10 CH2 group
with the planar aromatic p-xylyl function might be expected
to markedly increase the lipophilicity of the pigment and di-
minish its biliary excretion. In fact, it has the opposite e¡ect,
as shown by the markedly more polar behavior of 3 on HPLC
compared to bilirubin and by its rapid excretion in bile in
unconjugated form after intravenous administration. This is
undoubtedly because insertion of the p-xylyl group prevents 3
from forming the preferred, hydrogen-bonded lipophilic
Fig. 2. Biliary excretion pro¢les obtained after injecting 0.25 mg
each of bilirubin ditaurine amide (4) and extended rubin 3 simulta-
neously into (a) a Sprague^Dawley rat and (b) a TR3 rat. Open
circles represent 4 ; closed circles 3.
Fig. 3. Stereopair representations of the preferred conformations of
(upper) bilirubin IXK (1) and (lower) extended bilirubin (3). Hydro-
gen atoms are omitted. Light shading denotes O and N atoms, dark
shading C atoms.
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ridge^tile conformations that are characteristic of bilirubin in
solution and in the crystalline state [9^11]. Instead, as shown
by molecular mechanics calculations, 3 preferentially adopts a
sandwich type of structure (Fig. 3) in which some intramolec-
ular hydrogen bonding of the propionic acid groups to pyrro-
methenone lactam groups can still occur, but is weaker and
less complete than in bilirubin [17]. This has little apparent
e¡ect on hepatic uptake, since both bilirubin and 3 are taken
up rapidly by the liver from the circulation. But it has a
marked e¡ect on transhepatic transport and e¥ux into bile.
Whereas bilirubin is secreted rapidly into bile only after glu-
curonidation by UGT1A1, the extended rubin 3 was secreted
unchanged and at similar rates in both normal and Gunn rats.
This does not necessarily mean that 3 is not a substrate for
UGT1A1; merely that glucuronidation is not required for its
biliary excretion. However, we suspect that it is unlikely to be
a good substrate because it is unable to adopt the structural
motif 5 that seems to be preferred by the enzyme for e⁄cient
glucuronidation of bilirubins [14].
Stretched rubin 3 has many structural features present in
bilirubin glucuronides. Like them it is undoubtedly a dianion
at physiologic pH and on reversed phase HPLC it is even
more polar than bilirubin monoglucuronides. In addition it
has a hydrophobic aromatic benzene ring at the hinge region
of the molecule. It would thus appear to be an ideal candidate
for canalicular transport by Mrp2 [8,24]. Yet, it was excreted
promptly in bile after administration to TR3 rats that lack
Mrp2. Thus, it does not require the presence of Mrp2 for
e¥ux from the liver. In this respect it is similar to the ditau-
rine amide of bilirubin (4) [23], to the disulfonic acid indocya-
nin green [25,26], to the aliphatic hydroxylated carboxylic acid
privastatin [27], and to the glucuronide of the aromatic car-
boxylic acid telmisaltan [28], which do not require Mrp2 ei-
ther. However, its biliary excretion was impaired in TR3 rats,
which have a much slower bile £ow than either Gunn rats or
wild type animals. The biliary excretion curve was less sharp
and more prolonged than in rats with Mrp2, and the peak
concentration and proportion of the dose excreted within 4 h
was somewhat lower. This e¡ect was seen most clearly in
experiments in which 3 was injected along with ditaurobili-
rubin (4) as an internal standard. Ditaurobilirubin has been
shown to be excreted as e⁄ciently in TR3 rats as in normal
Mrp2-containing controls [23]. Although either compound
could potentially in£uence the excretion of the other, at the
trace doses used in our experiments we found no evidence for
this. In normal rats or Gunn rats, stretched rubin 3 showed
biliary excretion curves that were slightly delayed with respect
to those of ditaurobilirubin (Fig. 2a). This is consistent with
the greater HPLC polarity of ditaurobilirubin compared to 3.
In contrast, in the TR3 rat the di¡erence in the biliary ex-
cretion curves for the two compounds is much more pro-
nounced (Fig. 2b).
The slower excretion of 3 in TR3 rats compared to normal
rats would be consistent with the hypothesis that the com-
pound is, at least in part, actively transported into bile by
Mrp2. However, it is also possible that the e¡ect of Mrp2 is
a less direct one. Our data o¡er no insight into this question,
nor into the question of how 3 or ditaurobilirubin are secreted
into bile in the absence of Mrp2. It might be argued that they
are actively transported by some other canalicular organic
anion transporter. However, that argument merely raises the
alternative question of why the other transporter does not
facilitate the e¥ux of bilirubin glucuronides or even uncon-
jugated bilirubin.
These studies show the crucial role that intramolecular hy-
drogen bonding and three-dimensional structure can play in
the Phase II metabolism and hepatic transport of drugs and,
along with other studies [23,26^28], they suggest that Mrp2
might not be essential for the rapid e¥ux from liver to bile of
many non-bile salt organic anions.
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